Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working Party

Relapse of acute lymphoblastic leukemia (ALL) remains a major therapeutic challenge. Despite the consensus for proceeding to allogeneic stem cell transplantation (HSCT) in relapsing patients with ALL who achieve second complete remission (CR2) with salvage therapy, most patients lack a suitable matc...

Full description

Saved in:
Bibliographic Details
Published in:Bone marrow transplantation (Basingstoke) 2020-09, Vol.55 (9), p.1763-1772
Main Authors: Brissot, Eolia, Labopin, Myriam, Russo, Domenico, Martin, Sonja, Schmid, Christoph, Glass, Bertram, Ram, Ron, Ozkurt, Zubeyde Nur, Passweg, Jakob, Veelken, Joan Hendrik, Bunjes, Donald, Apperley, Jane, Giebel, Sebastian, Mohty, Mohamad, Nagler, Arnon
Format: Article
Language:English
Subjects:
Acute lymphoblastic leukemia
Acute lymphocytic leukemia
Care and treatment
Cord blood
Donors
Graft vs Host Disease
Graft-versus-host reaction
Health aspects
Hematopoietic Stem Cell Transplantation
Hematopoietic stem cells
Humans
Leukemia
Leukemia, Myeloid, Acute
Lymphatic leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy
Remission
Remission (Medicine)
Retrospective Studies
Stem cell transplantation
Stem cells
Survival
Transplantation
Transplantation Conditioning
Unrelated Donors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Relapse of acute lymphoblastic leukemia (ALL) remains a major therapeutic challenge. Despite the consensus for proceeding to allogeneic stem cell transplantation (HSCT) in relapsing patients with ALL who achieve second complete remission (CR2) with salvage therapy, most patients lack a suitable matched-related histocompatible donor. The present multicenter retrospective study compared, for ALL patients in CR2, the HSCT outcome from all four possible alternative hematopoietic stem cell sources, namely matched unrelated 10/10 (n = 281), mismatched unrelated 9/10 (n = 125), haploidentical (n = 105), and cord blood (n = 104) donors. The 2-year outcomes were not statistically different between the four donor sources with respect to overall survival (38.3-47.2%), leukemia-free survival (30.5-39.6%), relapse incidence (32.6-37.6%), nonrelapse mortality (27.5-34.6%), and graft-versus-host disease-free relapse survival (21.4-33.1%). Donor choices for ALL patients achieving CR2 post first relapse are broad, ensuring that most patient in need secures a graft. Therefore, in practice, the donor choice should depend on timely availability and policy center.
ISSN:0268-3369
1476-5365
DOI:10.1038/s41409-020-0849-x